Abstract:Huntington's disease (HD) is an inherited progressive neurodegenerative disorder characterized by motor dysfunction and premature mortality. Luteolin, a natural flavonoid with known antioxidant and neuroprotective properties, has shown promise in various neurodegenerative diseases. This study aimed to evaluate the potential benefits of luteolin treatment in a mouse model of (HD). To assess the effects of luteolin treatment, HD N171 82Q transgenic mice received luteolin administration, while another group received a vehicle treatment for comparison. The mice's body weight changes and survival rates were monitored throughout the study. Additionally, they underwent a series of motor function tests, including the rotarod test, balance beam test, and limb clasping test. Immunohistochemical staining and western blotting were utilized to assess the localization and expression of huntingtin aggregates, respectively. Findings revealed a significant protective effect of luteolin treatment against premature mortality and prevented weight loss in HD mice compared to the non‐luteolin‐treated group. Furthermore, the luteolin‐treated mice exhibited enhanced motor coordination and balance and significantly reduced motor dysfunction‐related manifestations, such as dystonic movements. Immunohistochemistry analysis and protein quantification demonstrated a decrease in the accumulation of huntingtin aggregates in the brain's cortex, hippocampus, and striatum of luteolin‐treated mice compared to the vehicle‐treated group. These findings collectively indicate that luteolin holds promise as a therapeutic agent for managing motor dysfunction, reducing huntingtin aggregations, and improving survival outcomes in individuals affected by Huntington's disease. The findings are of significance as currently, there are no approved therapeutic interventions that reverse HD pathology or slow down its progression. Aims The study aimed to evaluate the potential benefits of luteolin treatment in Huntington's disease (HD), an inherited progressive neurodegenerative disorder. Methods HD N171‐82Q transgenic and WT mice received luteolin or vehicle for treatment at 6 weeks of age. The mice's body weight changes and survival rates were monitored throughout the study, and a series of motor functional tests were conducted. Serum level of the marker NfL was also determined. Immunohistochemical staining and western blotting were utilized to assess the expression of huntingtin aggregates. Results Luteolin treatment enhanced survival and prevented weight loss in HD mice compared to the vehicle‐treated HD group. Furthermore, the luteolin‐treated HD mice exhibited enhanced motor coordination and balance and significantly reduced motor dysfunction. Also, luteolin decreased serum NfL levels in HD mice. Notably, the accumulation of huntingtin aggregates was significantly reduced in the brain's cortex, hippocampus, and striatum of luteolin‐treated HD mice compared to the vehicle‐treated HD group. Conclusion Luteolin holds promise as a therapeutic agent for improving survival outcomes, managing motor dysfunction, and reducing huntingtin aggregates in HD. The findings are of significance as currently, there are no approved therapeutic interventions that reverse HD pathology or slow down its progression.

Luteolin Protects Against 6-Hydoroxydopamine-Induced Cell Death via an Upregulation of HRD1 and SEL1L

Luteolin Protects Pc12 Cells from Rotenone-Induced Apoptosis

Luteolin Mitigates Dopaminergic Neuron Degeneration and Restrains Microglial M1 Polarization by Inhibiting Toll Like Receptor 4

Luteolin protects microglia against rotenone-induced toxicity in a hormetic manner through targeting oxidative stress response, genes associated with Parkinson’s disease and inflammatory pathways

Effects of L-dopa on Cells Expressing D2 Receptors and Level of Dopamine Transmitter in Hemiparkinsonian Rats

Neuroprotective Effect of Dioscin against Parkinson's Disease via Adjusting Dual-Specificity phosphatase 6(DUSP6)-Mediated Oxidative Stress

Puerarin Protects Dopaminergic Neurons in Parkinson’s Disease Models

Salidroside Protects Against 6-Hydroxydopamine-induced Cytotoxicity by Attenuating ER Stress

Endoplasmic Reticulum Stress Contributes to the Cell Death Induced by UCH-L1 Inhibitor.

Resveratrol Partially Prevents Rotenone-Induced Neurotoxicity in Dopaminergic SH-SY5Y Cells through Induction of Heme Oxygenase-1 Dependent Autophagy

Neuroprotective Effect of Luteolin-7-O-Glucoside against 6-OHDA-Induced Damage in Undifferentiated and RA-Differentiated SH-SY5Y Cells

Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic Cells

Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model

Neuroprotective Effects of Tanshinone I Against 6-Ohda-induced Oxidative Stress in Cellular and Mouse Model of Parkinson’s Disease Through Upregulating Nrf2

Lactoferrin Protects Against Rotenone-Induced Toxicity in Dopaminergic SH-SY5Y Cells through the Modulation of Apoptotic-Associated Pathways

Hesperetin Protects SH-SY5Y Cells Against 6-Hydroxydopamine-induced Neurotoxicity Via Activation of NRF2/ARE Signaling Pathways

Polydatin Prevents Lipopolysaccharide (LPS)-Induced Parkinson's Disease via Regulation of the AKT/GSK3β-Nrf2/NF-κB Signaling Axis

Luteolin attenuates oxidative stress in mice with cerebral ischemia-reperfusion by inhibiting Drp1 activation and promoting autophagy flux

Effect of luteolin on the behavior of levodopa induced dyskinesia rat model and the possible mechanisms

Luteolin protects against myocardial ischemia/reperfusion injury by reducing oxidative stress and apoptosis through the p53 pathway

Implication of the c-Jun-NH2-terminal kinase pathway in the neuroprotective effect of puerarin against 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in PC-12 cells